Valuation dashboard for Allogene Therapeutics, Inc. (ALLO) with P/E N/A, P/B 1.14, EV/EBITDA -4.19 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy.
Analysis Summary
Trailing-twelve-month margins: gross margin -7.0%, operating margin -38.9%, net margin -35.7%.
At the current price of $1.69, ALLO has negative trailing earnings (P/E not meaningful) and an ROE of -50.04%. Market capitalisation stands at $583M.
Balance sheet quality for ALLO: current ratio of 7.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.14 |
| EV / EBITDA | -4.19 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-0.15 |
| vs Current Price | -109.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | $583M | 1.14 | -50.0% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.69 |
| Market Cap | $583M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -50.04% |
| Return on Invested Capital | -34.79% |
| Return on Assets | -30.08% |
| Gross Margin | -699.35% |
| Operating Margin | -3886.14% |
| Net Margin | -3566.68% |
Related companies: ACHV · AVIR · CABA · CRBU · EDIT · HUMA · IMMP
Explore sector: Healthcare · Biotechnology
More sections of ALLO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks